Radiopharm (RADX) Theranostics announced that it has been granted Bellberry Human Research Ethics Committee, HREC, approval in Australia to initiate its First-In-Human, FIH, Phase 1 clinical trial of its Kallikrein Related Peptidase 3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or locally advanced prostate cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm announces 50% enrollment in Phase 2b trial of RAD101
- Radiopharm starts enrollment of third cohort in Phase 1 trial of 177Lu-RAD204
- Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Resolutions
- Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating
- Radiopharm Theranostics Announces November AGM with Key Resolutions